Trial Profile
A Phase 1b/2a Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability and Efficacy of Adjunctive Treatment With Topically Applied MBN-101 in Patients With Moderate to Severe Diabetic Foot Infection (DFI)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Apr 2024
Price :
$35
*
At a glance
- Drugs Pravibismane (Primary)
- Indications Bacterial infections; Diabetic foot ulcer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Microbion Corporation
- 04 Apr 2024 According to a Microbion Corporation media release, data from the study were presented in International Wound Journal.
- 04 Apr 2024 Results (from Phase 1b) presented in the Microbion Corporation Media Release.
- 01 Apr 2024 According to Microbion Corporation media release, the company has been selected to present topical pravibismane for the treatment of diabetic foot infection (DFI) at the Advanced Wound Care Summit USA held at the Boston Marriot Long Wharf from April 16th to 17th.